Market capitalization | $25.88m |
Enterprise Value | $25.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 20.25 |
P/S ratio (TTM) P/S ratio | 20.54 |
P/B ratio (TTM) P/B ratio | 4.21 |
Revenue growth (TTM) Revenue growth | 15.33% |
Revenue (TTM) Revenue | $1.26m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Femasys Inc forecast:
4 Analysts have issued a Femasys Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1.26 1.26 |
16%
16%
|
|
Gross Profit | -0.07 -0.07 |
59%
59%
|
|
EBITDA | -17 -17 |
36%
36%
|
EBIT (Operating Income) EBIT | -18 -18 |
34%
34%
|
Net Profit | -18 -18 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. Its products include FemVue Saline-Air Device, which creates and delivers an alternating pattern of saline and air as a continuous stream, and enables physicians to assess their patients fallopian tubes, and FemChec Pressure Management Device, which limits the maximum applied pressure while performing hysterosalpingogram. The firm offers FemCerv, an endocervical curettage device to collect a non-contaminated tissue sample for cervical cancer screening. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.
Head office | United States |
CEO | Kathy Lee-Sepsick |
Employees | 32 |
Founded | 2004 |
Website | www.femasys.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.